RNLX Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.23 |
| 52 Week High | UK£4.04 |
| 52 Week Low | UK£0.22 |
| Beta | 2.19 |
| 11 Month Change | -44.31% |
| 3 Month Change | -72.01% |
| 1 Year Change | -92.09% |
| 33 Year Change | -99.18% |
| 5 Year Change | n/a |
| Change since IPO | -98.29% |
Recent News & Updates
Recent updates
Renalytix: The Investment Case Is Shot
Jul 25Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M
Jun 30Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout
Apr 05Renalytix: Laying The Foundations For Growth
Jan 05Renalytix: Building Out A Capability To Ramp Revenue
Oct 20Renalytix AI EPS beats by $0.06, misses on revenue
Jun 15Centers for Medicaid & Medicare establishes MICT pathway
Jan 13Exact and Exact Sciences trade higher; Seen as beneficiaries from new CMS rule
Jan 12Renalytix AI EPS misses by $0.04
Nov 25Shareholder Returns
| RNLX | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -48.9% | -0.9% | 0.07% |
| 1Y | -92.1% | -21.5% | 20.7% |
Return vs Industry: RNLX underperformed the US Healthcare Services industry which returned -21.8% over the past year.
Return vs Market: RNLX underperformed the US Market which returned 20.7% over the past year.
Price Volatility
| RNLX volatility | |
|---|---|
| RNLX Average Weekly Movement | 17.4% |
| Healthcare Services Industry Average Movement | 9.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: RNLX's share price has been volatile over the past 3 months.
Volatility Over Time: RNLX's weekly volatility has decreased from 41% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| RNLX fundamental statistics | |
|---|---|
| Market cap | US$21.47m |
| Earnings (TTM) | -US$37.49m |
| Revenue (TTM) | US$2.22m |
9.7x
P/S Ratio-0.6x
P/E RatioIs RNLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNLX income statement (TTM) | |
|---|---|
| Revenue | US$2.22m |
| Cost of Revenue | US$2.26m |
| Gross Profit | -US$35.00k |
| Other Expenses | US$37.45m |
| Earnings | -US$37.49m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | -1.58% |
| Net Profit Margin | -1,687.80% |
| Debt/Equity Ratio | -84.1% |
How did RNLX perform over the long term?
See historical performance and comparison